Grifols (GIFLF) Operating Income (2010 - 2025)
Grifols' (GIFLF) quarterly Operating Income came in at $1.4 billion in Q4 2025, up 13.59% on a YoY basis from $1.3 billion in Q4 2024, and up 13.59% quarter-over-quarter from $1.3 billion in Q4 2024.
Analysis
Grifols (GIFLF) Operating Income (2010 - 2025) Analysis & Trends
Grifols (GIFLF) has reported Operating Income for 14 consecutive years, with $1.4 billion the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Operating Income rose 13.59% year-over-year to $1.4 billion; the trailing twelve-month figure through Dec 2025 stood at $2.5 billion (up 22.0% YoY), and the FY2025 full-year result was $1.4 billion, up 10.25% from the prior year.
- Operating Income improved to $1.4 billion in Q4 2025 per GIFLF's latest filing, from $1.3 billion in the prior quarter.
- Across five years, Operating Income topped out at $1.4 billion in Q4 2025 and bottomed at -$133.4 million in Q4 2021.
- Historically, Operating Income has averaged $862.4 million across 3 years, with a median of $1.3 billion in 2024.
- The sharpest annual moves came in 2021 and 2025: Operating Income retreated 0.54% in 2021, then grew 13.59% in 2025.
- Over 3 years, Operating Income stood at -$133.4 million in 2021, then soared by 1054.98% to $1.3 billion in 2024, then grew by 13.59% to $1.4 billion in 2025.
- According to Business Quant data, Operating Income over the past three periods registered $1.4 billion, $1.3 billion, and -$133.4 million for Q4 2025, Q4 2024, and Q4 2021 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 203.97 Bn | 189.99 Bn | 7.24 Bn | 3.51 Bn |
| 2 | Gilead Sciences | 178.74 Bn | 175.56 Bn | 6.22 Bn | -10.39 Bn |
| 3 | Vertex Pharmaceuticals | 130.73 Bn | 122.88 Bn | 2.84 Bn | 1.25 Bn |
| 4 | Regeneron Pharmaceuticals | 80.42 Bn | 72.42 Bn | 3.93 Bn | 1.29 Bn |
| 5 | Argenx Se | 60.40 Bn | 55.21 Bn | 1.37 Bn | 493.00 Mn |
| 6 | Moderna | 57.65 Bn | 52.52 Bn | 52.00 Mn | -815.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.37 Bn | 30.07 Bn | 992.69 Mn | 231.44 Mn |
| 8 | Biogen | 32.15 Bn | 30.86 Bn | 1.96 Bn | -644.50 Mn |
| 9 | Roivant Sciences | 29.58 Bn | 29.58 Bn | 1.16 Mn | -365.99 Mn |
| 10 | Grifols | 7.54 Bn | 9.09 Bn | 3.33 Bn | 1.45 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 1.45 Bn |
| Dec 31, 2024 | 1.27 Bn |
| Dec 31, 2021 | -133.38 Mn |
| Dec 31, 2020 | -132.66 Mn |
| Mar 31, 2020 | 1.00 Bn |
| Dec 31, 2019 | 2.91 Bn |
| Mar 31, 2019 | 937.75 Mn |
| Dec 31, 2018 | 252.39 Mn |
| Jun 30, 2018 | 312.31 Mn |
| Mar 31, 2018 | 300.50 Mn |
| Dec 31, 2017 | 944.89 Mn |
| Jun 30, 2017 | 313.51 Mn |
| Mar 31, 2017 | 269.23 Mn |
| Dec 31, 2016 | 488.79 Mn |
| Sep 30, 2016 | 267.29 Mn |
| Jun 30, 2016 | 257.31 Mn |
| Mar 31, 2016 | 255.35 Mn |
| Dec 31, 2015 | 787.01 Mn |
| Sep 30, 2015 | 275.09 Mn |
| Jun 30, 2015 | 258.96 Mn |